AI assistant
AbbVie Inc. — Director's Dealing 2022
Oct 27, 2022
29755_dirs_2022-10-27_9a9b80fa-4d22-47fd-849b-6c435d018615.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2022-10-17
Reporting Person: Siatis Perry C (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.01 par value | 10377 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option (Right to buy) | $93.50 | 2030-02-19 | Common Stock (7364) | Direct | |
| Option (Right to buy) | $105.92 | 2031-02-17 | Common Stock (7039) | Direct | |
| Option (Right to buy) | $144.54 | 2032-02-16 | Common Stock (8756) | Direct |
Footnotes
F1: These securities represent restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. They vest in full on February 17, 2025, and include the right to have stock withheld for tax purposes.
F2: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,365 shares on 2/20/2021 and as to 7,365 shares on 2/20/2022, and will become exercisable as to 7,364 shares on 2/20/2023.
F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,250 shares on 2/18/2022, and will become exercisable as to 3,250 shares on 2/18/2023 and as to 3,519 shares on 2/18/2024.
F4: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,919 shares on 2/17/2023, as to 2,919 shares on 2/17/2024 and as to 2,918 shares on 2/17/2025.